Shailender Bhatia, MD, on Merkel Cell Carcinoma: Final Results of a Phase II Study
2015 European Cancer Congress
Shailender Bhatia, MD, of the Fred Hutchinson Cancer Center, discusses his paper on interleukin-12 DNA and regression of Merkel cell tumors (Abstract 504).
Michael Pfreundschuh, MD
Michael Pfreundschuh, MD, of Universitaetsklinikum des Saarlandes, summarizes a session he chaired on this topic, which covered Burkitt’s lymphoma as well as lymphoblastic leukemia in children and adults.
Martine J. Piccart-Gebhart, MD, PhD
Martine J. Piccart-Gebhart, MD, PhD, of the Jules Bordet Institute, and ECCO President, discusses ways in which imaging can form the solution to individualized cancer treatment.
Jean-Charles Soria, MD, PhD
Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: afatinib vs erlotinib in squamous cell carcinoma of the lung.
Clifford A. Hudis, MD
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discusses this prospective study of endocrine therapy alone in patients with ER-positive, HER2-negative, node-negative breast cancer (Abstract 5BA).
Rolf A. Stahel, MD
Rolf A. Stahel, MD, of University Hospital, Zurich, discusses this phase II trial of erlotinib and bevacizumab in patients with advanced, EGFR-mutated non-small cell lung cancer without T790M mutation. The study was sponsored by The Spanish Lung Cancer Group and the European Thoracic Oncology Platform (Abstract 3BA).